4 Needs context
Recent clinical guidelines recommend initiating statins for patients with an LDL cholesterol level above 55 mg/dL.
"Now it's 55. If your LDL is over 55, some of the guidelines are talking about saying start a statin." (said at 0:03:23)
The speaker's statement needs context regarding the patient population and the distinction between a universal initiation threshold versus a therapeutic target for very-high-risk individuals. Guidelines such as the 2019 ESC/EAS dyslipidemia guidelines lowered the LDL cholesterol goal/threshold to <55 mg/dL (1.4 mmol/L) specifically for individuals at very high cardiovascular risk (e.g., established atherosclerotic cardiovascular disease). For the general population or low/moderate-risk primary prevention, guidelines do not recommend initiating statins solely based on an LDL-C level exceeding 55 mg/dL; higher baseline thresholds and overall absolute cardiovascular risk scoring are used.
Three-quarters of physicians, including internists, cardiologists, and family practitioners, do not know how to diagnose pre-diabetes and insulin resistance.
"Again, it's been demonstrated multiple times that three quarters of doctors don't know how to diagnose metabolic disease. And I'm not talking about orthopedists and surgeons here. I'm talking about the people that are supposed to be doing this. Internists, even cardiologists, family practitioners—three quarters of them don't know how to diagnose pre-diabetes, insulin resistance." (said at 0:11:31)
Surveys of primary care providers have demonstrated substantial knowledge gaps regarding the exact formal laboratory diagnostic cutoffs and screening guidelines for prediabetes. For example, a survey of academic primary care providers found that only 17% correctly identified the laboratory parameters for diagnosing prediabetes based on both fasting glucose and HbA1c (meaning >80% failed to correctly identify all exact laboratory diagnostic criteria). A broader national survey of US primary care physicians similarly identified limited knowledge of diagnostic criteria and risk factors. However, the speaker's phrasing that 'three quarters of doctors don't know how to diagnose metabolic disease/insulin resistance' overstates specific survey findings about recall of American Diabetes Association numeric cutoffs as an inability to diagnose metabolic disease, and cardiologists were not specifically evaluated in these primary care provider surveys.
Research published by Dr. Aseem Malhotra found that taking statins for several years only extends lifespan by an average of a few days.
"On one side, you have Dr. Malhotra who appeared on Joe Rogan talking about this specific aspect about statins will add only a couple of days of life after a couple of years of taking them." (said at 0:19:33)
The cited figure comes from a 2015 systematic review by Kristensen et al. published in BMJ Open (which Dr. Aseem Malhotra frequently cites in media appearances, though was not an author on). Analyzing 11 randomized trials with follow-up durations between 2.0 and 6.1 years, the authors calculated a median postponement of death of 3.2 days in primary prevention and 4.1 days in secondary prevention over the trial periods. However, interpreting this as statins extending lifespan by only a few days requires essential context: this metric averages survival time across the entire study population over a short trial window during which the overwhelming majority of participants survived regardless of treatment. It does not reflect lifetime life expectancy gains or the substantial survival benefit accrued by individuals who avoided fatal cardiovascular events.
For secondary prevention in patients who have had a heart attack, treating about 80 people with statins over 5 years prevents one death.
"For secondary prevention, patients who've already had a heart attack, you need to treat about 80 people over 5 years and you prevent one death." (said at 1:06:38)
Randomized controlled trials and meta-analyses of statin therapy for secondary prevention of cardiovascular disease show that statins reduce all-cause mortality over a 5-year treatment period, but the specific Number Needed to Treat (NNT) varies depending on the baseline risk of the population and the specific study synthesized. In early landmark trial meta-analyses of secondary prevention (e.g., standard lipid-lowering trials including the 4S, CARE, and LIPID trials), the NNT over approximately 5 years to prevent one all-cause death in patients with established coronary heart disease was approximately 37 (PMID: 8656168). Across broader modern meta-analyses including less selected populations or varying intensities of lipid lowering, the overall NNT to prevent one all-cause death over a shorter timeframe or annualized trial duration is higher (PMID: 36027598).
While an NNT of roughly 80 over 5 years is within the range reported in various secondary prevention analyses (often quoted between ~30 and ~80 depending on whether the primary endpoint is all-cause mortality, cardiovascular mortality, or major adverse cardiovascular events), the specific spoken figure of 80 for all-cause death in post-myocardial infarction patients requires context regarding the specific trial baseline risk, endpoint, and treatment duration.
18 Supported by research
Over 200 million people worldwide take statins on a daily basis.
"Because over 200 million people are taking them on a daily basis." (said at 0:00:01)
Epidemiological reviews and biomedical literature widely estimate that more than 200 million people worldwide are currently prescribed and taking statin therapy on a daily basis for the management of dyslipidemia and prevention of cardiovascular disease.
Under current US guidelines, 40% or more of older adults qualify for a statin for primary prevention.
"So, under US guidelines, current guidelines, 40% or more of older adults would qualify for a statin for primary prevention." (said at 0:03:56)
Nationally representative analyses of US adults in the National Health and Nutrition Examination Survey (NHANES) demonstrate that under the 2018 AHA/ACC/Multisociety cholesterol guidelines, approximately 46.8% of adults aged 40 to 75 without atherosclerotic cardiovascular disease qualify for primary prevention statin therapy. Among older adults specifically (ages 60 to 75 years without preexisting cardiovascular disease), eligibility under ACC/AHA risk equations exceeds 50% for women and 80% for men.
- supports: Application of new cholesterol guidelines to a population-based sample. (The New England journal of medicine 2014) · cited 618x in the literature
"Among adults between the ages of 60 and 75 years without cardiovascular disease who are not receiving statin therapy, the percentage who would be eligible for such therapy would increase from 30.4% to 87.4% among men and from 21.2% to 53.6% among women." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Comparing eligibility for statin therapy for primary prevention under 2022 USPSTF recommen… (Progress in cardiovascular diseases 2022) · cited 15x in the literature
"The 2022 USPSTF recommendations and the 2018 AHA/ ACC/ MS Cholesterol guidelines indicated eligibility for statin therapy in 31.8% (95% CI 28.6, 35.1) and 46.8% (95% CI 43.0, 50.5) adults, respectively. These represent 33.7 million (95% CI 30.4, 37.2) and 49.7 million (95% CI 45.7, 53.7) adults, respectively." (abstract, results, passage verified)
pubmedfull study (doi)
In primary prevention, the actual cardiovascular risk reduction provided by statins over 5 years is often in the single digits.
"Primary prevention, the actual risk reduction over 5 years is often in single digits." (said at 0:05:38)
High-certainty evidence from large meta-analyses of randomized clinical trials demonstrates that in primary prevention populations, the absolute risk reduction (ARR) in cardiovascular events and mortality with statin therapy over a typical trial duration (around 3 to 5 years) is modest and consistently in the single digits (typically ranging from under 1% to around 1% to 3%). For example, a comprehensive systematic review and meta-analysis of 21 randomized clinical trials found that statin therapy was associated with absolute risk reductions of 0.8% for all-cause mortality, 1.3% for myocardial infarction, and 0.4% for stroke.
- supports: Evaluating the Association Between Low-Density Lipoprotein Cholesterol Reduction and Relat… (JAMA internal medicine 2022) · cited 112x in the literature
"Meta-analyses showed reductions in the absolute risk of 0.8% (95% CI, 0.4%-1.2%) for all-cause mortality, 1.3% (95% CI, 0.9%-1.7%) for myocardial infarction, and 0.4% (95% CI, 0.2%-0.6%) for stroke in those randomized to treatment with statins, with associated relative risk reductions of 9% (95% CI, 5%-14%), 29% (95% CI, 22%-34%), and 14% (95% CI, 5%-22%) respectively." (abstract, results, passage verified)
pubmedfull study (doi)
A major clinical trial reported a 46% relative risk reduction in strokes with statins, which translated to an absolute risk reduction of 1.3% (13 fewer strokes per 1,000 people over 4 years).
"One major trial reported a 46% relative reduction in strokes. And that sounds like a powerful drug, but when you convert that to real-world terms and look at absolute risk, not relative risk, it was 1.3%. ... So, with the 1.3% was really 13 fewer strokes per thousand people over 4 years." (said at 0:06:52)
The speaker's figures correspond directly to the landmark Collaborative Atorvastatin Diabetes Study (CARDS), a multicenter randomized placebo-controlled trial of atorvastatin (10 mg daily) in 2,838 patients with type 2 diabetes. Over a median follow-up of 3.9 years, atorvastatin reduced stroke incidence with a relative risk reduction of 48% (95% CI 11% to 69%), which corresponded to an absolute risk reduction of approximately 1.3% (from 2.8% in the placebo group to 1.5% in the atorvastatin group, or ~13 fewer stroke events per 1,000 treated patients over roughly 4 years).
Statins have generated an estimated $1 trillion in global cumulative sales, and the US statin market alone was valued at $4.5 billion in 2023.
"Statins have generated an estimated $1 trillion dollars in global sales. The US market alone was valued at 4.5 billion even in 2023." (said at 0:15:25)
Published literature reports that global cumulative sales of statins were projected to reach approximately $1 trillion. Industry and market analyses similarly value the contemporary annual US statin market in the range of several billion dollars (~$4.5 billion in 2023), reflecting continued high prescribing volumes despite widespread generic availability.
Research in Massachusetts found that physicians who received payments from pharmaceutical companies prescribed measurably more brand-name statins.
"Researchers in Massachusetts found that doctors who received payments from drug companies, that does happen, and they prescribe measurably more brand-name statins" (said at 0:17:03)
A 2016 cross-sectional study linking the Massachusetts physician payment database with 2011 Medicare Part D prescribing claims evaluated 2,444 physicians who prescribed statins. The researchers found that industry payments were significantly associated with increased rates of prescribing brand-name statins (an increase of 0.1% per $1,000 in total payments received, P < .001, and a 4.8% increase associated with payments for educational training, P = .004).
Coronary artery calcium (CAC) scoring only detects calcified arterial plaque and cannot identify soft (non-calcified) plaque.
"Well, we know people have had nothing but soft plaque on a calcium score. In other words, calcium score only stabilized calcified plaque." (said at 0:23:38)
Coronary artery calcium (CAC) scoring utilizes non-contrast computed tomography specifically to measure and quantify high-density calcified plaque. Studies comparing non-contrast calcium scoring with contrast-enhanced coronary CT angiography (CTCA) show that non-calcified (soft) coronary plaques can be present in individuals with a CAC score of zero. Standard non-contrast CAC scoring has a very low sensitivity (39%) for identifying non-calcified plaque, requiring contrast CT angiography for reliable evaluation.
- supports: The presence, characterization and prognosis of coronary plaques among patients with zero … (The international journal of cardiovascular imaging 2011) · cited 27x in the literature
"The prevalence of coronary plaque was 13% (147 patients). Among the 212 plaques identified 154 (73%) were non-calcified, 28 (13%) were calcified, and 30 (14%) were of mixed morphology." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Can non-calcified coronary artery plaques be detected on non-contrast CT calcium scoring s… (Academic radiology 2011) · cited 4x in the literature
"The overall positive predictive value for correct identification of noncalcified plaque on calcium scoring studies was 0.88, although overall sensitivity was low at 0.39." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Coronary atherosclerosis on AI-based plaque analysis in patients with chest pain and calci… (The international journal of cardiovascular imaging 2026) · cited 3x in the literature
"Non-calcified plaques dominated, but small calcifications were not uncommon." (abstract, results, passage verified)
pubmedfull study (doi)
A Danish meta-analysis of statin trials for secondary prevention showed that the average gain in life expectancy across the analyzed group was approximately 4 days.
"He was quoting a Danish meta-analysis. It was a large pooled analysis of several statin trials for secondary prevention, meaning patients who had already had a heart attack. Now, that's how they were defining secondary prevention. They were not defining secondary prevention as they had plaque. They were not very clear about who had metabolic disease. The average gain in life expectancy across that whole group was about 4 days. Days, not years." (said at 0:37:29)
A 2015 Danish systematic review and meta-analysis by Kristensen and colleagues published in BMJ Open analyzed randomized trials of statins to estimate the average postponement of death within trial follow-up periods (ranging from 2.0 to 6.1 years). For secondary prevention trials (5 studies), the median postponement of death across the analyzed cohorts was 4.1 days (ranging from -10 to 27 days).
The euglycemic hyperinsulinemic clamp is the gold standard for measuring insulin resistance.
"Researchers use the gold standard for measuring insulin resistance: it's called a euglycemic hyperinsulinemic clamp." (said at 0:48:50)
The statement is fully supported. The hyperinsulinemic-euglycemic clamp (also termed the euglycemic-hyperinsulinemic clamp) is universally recognized in biomedical and metabolic research as the gold standard reference technique for directly quantifying insulin sensitivity and insulin resistance in humans. Because the procedure requires continuous intravenous infusions of insulin and glucose with frequent blood sampling to maintain steady euglycemia, surrogate markers (such as HOMA-IR or TyG index) are typically used in routine clinical practice, while the clamp remains the definitive research standard.
Rosuvastatin is approximately twice as potent as atorvastatin milligram for milligram.
"Rosuvastatin is twice as strong about as atorvastatin. Those are the two more common ones that you see. So, a dose of uh 20 mg, for example, for rosuvastatin is equal to uh a dose of uh 40 of atorvastatin." (said at 0:59:15)
Clinical trial evidence and standard guideline dose equivalencies confirm that rosuvastatin is roughly twice as potent as atorvastatin milligram-for-milligram in lowering low-density lipoprotein cholesterol (LDL-C). In large multicenter randomized comparative trials such as the STELLAR study, rosuvastatin demonstrated superior LDL-C reductions across comparable milligram doses, establishing the standard dose equivalence where 10 mg and 20 mg of rosuvastatin provide LDL-C lowering comparable to 20 mg and 40 mg of atorvastatin, respectively.
Japanese studies have demonstrated that combining very low-dose rosuvastatin (2.5 mg or 5 mg) with ezetimibe leads to arterial plaque regression.
"But you also need to consider that there is rosuvastatin 2.5 or five, and we have seen research where you combine rosuvastatin in very low dose and ezetimibe, and both have an impact on even arterial plaque reversal. Couple of Japanese studies have shown that." (said at 1:00:10)
Japanese clinical trials using intravascular ultrasound (IVUS) have demonstrated that combining low-dose statin therapy (such as rosuvastatin 5 mg/day or low-to-moderate dose atorvastatin) with ezetimibe (10 mg/day) promotes coronary plaque regression. For example, a prospective randomized study in Japanese patients with coronary artery disease evaluated rosuvastatin 5 mg plus ezetimibe 10 mg versus rosuvastatin 5 mg monotherapy, finding a significant reduction in coronary plaque volume (-13.2% vs. -3.1%). Similarly, the Japanese multicenter PRECISE-IVUS trial demonstrated superior coronary atheroma regression when ezetimibe was added to statin therapy.
- supports: Effect of combination therapy of ezetimibe and rosuvastatin on regression of coronary athe… (International heart journal 2015) · cited 61x in the literature
"In this prospective randomized open-label study, a total of 51 patients with stable coronary artery disease (CAD) requiring percutaneous coronary intervention (PCI) were enrolled, and assigned to a combination group (n = 26, rosuvastatin 5 mg/day + ezetimibe 10 mg/day) or a monotherapy group (n = 25, rosuvastatin 5 mg/day)... The percent change in plaque volume (PV), the primary endpoint, appeared to decrease more effectively in the combination group compared with the monotherapy group (-13.2% versus -3.1%, respectively, P = 0.050)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque … (Journal of the American College of Cardiology 2015) · cited 454x in the literature
"For PAV, a significantly greater percentage of patients who received atorvastatin/ezetimibe showed coronary plaque regression (78% vs. 58%; p = 0.004)... Compared with standard statin monotherapy, the combination of statin plus ezetimibe showed greater coronary plaque regression, which might be attributed to cholesterol absorption inhibition-induced aggressive lipid lowering." (abstract, results and conclusions)
pubmedfull study (doi)
Data from NHANES studies indicates that approximately 50% to nearly 90% of the American population is metabolically compromised or unhealthy.
"So, if you're already metabolically compromised and as we said, that's only about what? 50% of us as shown by the NHANES study a couple of years ago and more like 90% of us, a high-dose statin isn't just a heart drug." (said at 0:53:10)
Nationally representative data from the National Health and Nutrition Examination Survey (NHANES) support the claim. An analysis of NHANES 2009–2016 data by Araújo et al. (2019) evaluated cardiometabolic parameters (waist circumference, fasting glucose/HbA1c, blood pressure, triglycerides, and HDL cholesterol without medication) and found that only 12.2% of US adults met criteria for optimal metabolic health, indicating that approximately 88% were metabolically compromised. A subsequent analysis of NHANES 1999–2018 data by O'Hearn et al. (2022) found that by 2017–2018, optimal cardiometabolic health had declined to just 6.8% of US adults (over 93% suboptimal). Depending on whether less stringent criteria (such as older ATP III definitions or individual risk thresholds) or strict multi-parameter definitions are applied, estimates of metabolically suboptimal or compromised US adults range from roughly 50% to over 90%.
The risk of experiencing a recurrent heart attack is highest during the 6 to 12 months immediately following a myocardial infarction.
"and especially after a heart attack in the 6 months after a heart attack or a year, which is where you have the highest risk to have a a second heart attack" (said at 0:57:15)
Large nationwide registry cohorts and epidemiological studies demonstrate that the risk of recurrent ischemic cardiovascular events (including recurrent myocardial infarction) and cardiovascular death is sharply front-loaded, with the highest hazard rate occurring in the initial 6 to 12 months following an index myocardial infarction. In a nationwide Swedish registry cohort of 97,254 post-MI patients, the risk of a primary composite ischemic endpoint (non-fatal MI, stroke, or CV death) was 18.3% during the first 365 days post-index MI, compared to a cumulative 20.0% across the entire subsequent 3-year follow-up period (PMID: 25586123).
Evidence has not been substantial enough to prove that lowering lipoprotein(a) prevents heart attacks.
"Although the evidence hasn't been substantial enough to say you have to lower it to avoid a heart attack, but it gives that peace of mind of having suspenders and a belt" (said at 1:02:50)
The speaker accurately states that current evidence has not yet definitively established that specifically lowering lipoprotein(a) [Lp(a)] prevents heart attacks or major adverse cardiovascular events.
While epidemiological and genetic Mendelian randomization studies strongly link elevated Lp(a) to cardiovascular disease risk, dedicated clinical trials evaluating targeted Lp(a)-lowering therapies (such as pelacarsen, olpasiran, lepodisiran, and zerlasiran) designed to confirm whether lowering Lp(a) translates into a reduction in cardiovascular events like myocardial infarctions remain ongoing. Non-specific agents like PCSK9 inhibitors show secondary reductions in Lp(a) associated with risk reduction (e.g., in the ODYSSEY OUTCOMES trial), but direct clinical proof that lowering Lp(a) per se prevents heart attacks awaits the conclusion of dedicated phase 3 cardiovascular outcome trials.
- supports: Lipoprotein(a) as a Predictive Biomarker and Therapeutic Target for Acute Coronary Syndrom… (Current pharmaceutical design 2023) · cited 3x in the literature
"Results of ongoing phase-3 trials will answer whether Lp(a) will become a biomarker specifically treated to reduce the burden of cardiovascular mortality." (abstract, background, passage verified)
pubmedfull study (doi) - supports: New insights into the therapeutic options to lower lipoprotein(a). (European journal of clinical investigation 2024) · cited 19x in the literature
"If the results from the cardiovascular outcome trials, designed to demonstrate whether the reduction of Lp(a) of more than 80% as observed with pelacarsen, olpasiran or lepodisiran translates into the decrease of cardiovascular mortality and major adverse cardiovascular events, will be positive, lowering Lp(a) will become a new additional target in the management of patients with elevated cardiovascular risk." (abstract, conclusions, passage verified)
pubmedfull study (doi) - supports: Emerging Therapies Targeting Lipoprotein(a): A Clinical Trial Landscape Review of Investig… (Journal of clinical medicine 2026)
"Ongoing cardiovascular outcomes trials will determine whether these reductions translate into meaningful cardiovascular benefits, establish Lp(a) as a therapeutic target in cardiovascular prevention and clarify the long-term safety and risk-benefit profile of Lp(a)-targeted therapies." (abstract, conclusions, passage verified)
pubmedfull study (doi)
Nonsteroidal anti-inflammatory drugs (NSAIDs) do not reduce cardiovascular disease risk.
"They found that some anti-inflammatories like um the nonsteroidal anti-inflammatories, you would think, well, maybe that would help. No, they don't. They don't help at all." (said at 1:13:15)
Large meta-analyses of randomized clinical trials confirm that nonsteroidal anti-inflammatory drugs (NSAIDs)—including both selective COX-2 inhibitors and traditional NSAIDs—do not reduce cardiovascular disease risk. Instead, high-dose NSAID regimens (such as diclofenac, ibuprofen, and coxibs) significantly increase the risk of major coronary events, major vascular events, and heart failure, while naproxen does not confer vascular protection.
- supports: Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta… (Lancet (London, England) 2013) · cited 1799x in the literature
"Major vascular events were increased by about a third by a coxib (rate ratio [RR] 1·37, 95% CI 1·14-1·66; p=0·0009) or diclofenac (1·41, 1·12-1·78; p=0·0036), chiefly due to an increase in major coronary events (coxibs 1·76, 1·31-2·37; p=0·0001; diclofenac 1·70, 1·19-2·41; p=0·0032). Ibuprofen also significantly increased major coronary events (2·22, 1·10-4·48; p=0·0253), but not major vascular events (1·44, 0·89-2·33). [...] Naproxen did not significantly increase major vascular events (0·93, 0·69-1·27). [...] Heart failure risk was roughly doubled by all NSAIDs." (abstract, results, passage verified)
pubmedfull study (doi)
Inflammatory conditions like rheumatoid arthritis and psoriatic arthritis increase inflammation and heart attack risk as much as full diabetes mellitus does.
"Rheumatoid arthritis, uh psoriatic arthritis, those types of inflammation do significantly They cause as much inflammation and heart attack risk as full diabetes, whereas some other inflammatory diseases don't." (said at 1:13:35)
Large epidemiologic and cohort studies confirm that systemic inflammatory arthritides such as rheumatoid arthritis confer an elevated risk of myocardial infarction comparable to that of diabetes mellitus. A Danish nationwide cohort study of over 4.3 million individuals (Lindhardsen et al., 2011) demonstrated that the adjusted incidence rate ratio (IRR) for myocardial infarction was identical between patients with rheumatoid arthritis (IRR 1.7, 95% CI 1.5–1.9) and patients with diabetes mellitus (IRR 1.7, 95% CI 1.6–1.8; p = 0.64 for difference). Other prospective cohort data have likewise demonstrated comparable cardiovascular event rates between rheumatoid arthritis and diabetes populations.
Statin-induced new-onset diabetes and muscle side effects are dose-dependent and become significantly more pronounced at high doses.
"The diabetes signal and the muscle problems, they're dose-dependent... These side effects, the diabetes side effects, the muscle problems, those things get much worse at high doses." (said at 1:15:15)
Large-scale individual participant data meta-analyses of double-blind randomized controlled trials confirm that both new-onset diabetes and muscle-related adverse events are dose-dependent and occur at higher rates with intensive/high-dose statin regimens compared to moderate- or low-dose regimens. For diabetes, low-to-moderate intensity statins increase the rate of new-onset diabetes by approximately 10% (RR 1.10, 95% CI 1.04–1.16) compared with placebo, whereas high-intensity statins increase it by 36% (RR 1.36, 95% CI 1.25–1.48). Similarly, for muscle symptoms (pain or weakness), higher-intensity statin regimens confer a larger relative increase across all years (RR 1.08, 95% CI 1.04–1.13) compared with moderate- or low-intensity regimens (RR 1.03, 95% CI 1.00–1.05).
- supports: Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis … (Lancet (London, England) 2022) · cited 260x in the literature
"For all years combined, more intensive statin regimens (ie, 40-80 mg atorvastatin or 20-40 mg rosuvastatin once per day) yielded a higher RR than less intensive or moderate-intensity regimens (1·08 [1·04-1·13] vs 1·03 [1·00-1·05]) compared with placebo, and a small excess was present (1·05 [0·99-1·12]) for more intensive regimens after year 1." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in la… (The lancet. Diabetes & endocrinology 2024) · cited 151x in the literature
"Compared with placebo, allocation to low-intensity or moderate-intensity statin therapy resulted in a 10% proportional increase in new-onset diabetes (2420 of 39 179 participants assigned to receive a statin [1·3% per year] vs 2214 of 39 266 participants assigned to receive placebo [1·2% per year]; rate ratio [RR] 1·10, 95% CI 1·04-1·16), and allocation to high-intensity statin therapy resulted in a 36% proportional increase (1221 of 9935 participants assigned to receive a statin [4·8% per year] vs 905 of 9859 participants assigned to receive placebo [3·5% per year]; 1·36, 1·25-1·48)." (abstract, results, passage verified)
pubmedfull study (doi)
Red yeast rice contains the active chemical ingredient of early statin pharmaceuticals (monacolin).
"red yeast rice is—you know, it's related to—what's it called? It's got the active ingredients of one of the original statins in it... Monacolin, yeah, that's right. Yeah. Yeah. The active ingredient." (said at 1:20:28)
Red yeast rice contains monacolin K, an active lipid-lowering compound that is chemically identical to lovastatin, the first commercially approved statin pharmaceutical.
4 No source found (not proven false)
The Honda study shows that individuals with stable calcified plaque have approximately the same cardiovascular event risk as individuals with no plaque.
"even though you look at studies like the Honda study, which shows that people with stable plaque really have about the same risk as somebody with no plaque." (said at 0:24:50)
No published record matching the claim that the "Honda study" demonstrated individuals with stable calcified plaque have approximately the same cardiovascular event risk as individuals with no plaque was located; this does not prove the claim false. While cardiovascular literature extensively examines coronary artery calcification, plaque morphology, and subsequent event risk, no study authored by Honda or commonly referred to as the Honda study showing identical risk between calcified plaque and absence of plaque was identified.
High-dose atorvastatin increases insulin resistance by 8% to 24% within several weeks in patients without changes in diet or weight, as measured by euglycemic hyperinsulinemic clamp.
"Now, when you use that test, researchers found a couple of things. One, that high-dose atorvastatin—Lipitor, which is the brand name—it increased insulin resistance by 8 to 24% in just a few weeks. So, there was no change in diet, no change in weight in these patients." (said at 0:49:45)
No published record matching the claim that high-dose atorvastatin increases insulin resistance by 8% to 24% within several weeks as measured by euglycemic hyperinsulinemic clamp in patients without changes in diet or weight was located; this does not prove the claim false.
Statins exhibit pleiotropic anti-inflammatory effects that reduce C-reactive protein, Lp-PLA2, and the urine microalbumin-creatinine ratio, and promote plaque stabilization.
"Statins have what we call pleiotropic effects... in statins, that means uh you get an impact on inflammation. And so, what we're really interested in is what they actually do: C-reactive protein reduction in this case, inflammation, uh Lp-PLA2, microalbumin-creatinine uh ratio, plaque stabilization." (said at 1:10:52)
No published record matching the claim that statins exhibit pleiotropic anti-inflammatory effects that reduce C-reactive protein, Lp-PLA2, and the urine microalbumin-creatinine ratio, and promote plaque stabilization was located; this does not prove the claim false.
Low doses of statins are sufficient to impact vascular inflammation, lower CRP, improve endothelial function, and stabilize arterial plaque without needing high or moderate doses.
"So, what we're looking for is low-dose statins because the low-dose statins actually impact You don't need a high dose or even a mid dose to impact vascular inflammation, that CRP, that microalbumin-creatinine ratio. And what we're looking for is stabilization of the plaque." (said at 1:13:55)
No published record matching the claim that low-dose statins are sufficient to impact vascular inflammation, lower hs-CRP, improve endothelial function, and stabilize arterial plaque without needing moderate or high doses was located; this does not prove the claim false.
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.